22nd Dec 2006 09:47
BTG PLC22 December 2006 BTG licenses haemofiltration device patents to Fresenius Medical Care London, UK, 22 December 2006: BTG plc (LSE: BGC), the medical innovationscompany, today announces that it has granted Fresenius Medical Care AG & Co.KGaA a non-exclusive licence for the global rights to patents relating to ahaemofiltration device for €4.5 million fully paid. Developed by researchers at Cincinnati Children's Hospital, the device improvesthe treatment of acute renal failure by enabling automated adjustments to bemade during a haemofiltration session, reducing the possibility of human errorand the need for supervision. Louise Makin, BTG's Chief Executive Officer, said: "We are pleased to havesigned this agreement relating to the haemofiltration patents, and we areactively seeking additional licensees." For further information contact: BTG Financial DynamicsAndy Burrows, Director of Investor Relations Ben Atwell+44 (0)20 7575 1741; mobile: +44 (0)7990 530605 +44 (0)20 7831 3113Christine Soden, Chief Financial Officer+44 (0)20 7575 1591 About BTG BTG in-licenses, develops and commercialises pharmaceuticals and other medicaltechnologies. With a substantial and growing revenue stream of royalties andmilestone payments from out-licensed products, BTG continues to strengthen itspipeline of preclinical and clinical development programmes. Active in thefields of oncology, diseases of ageing, neuroscience, drug repositioning andmedical devices, BTG works from its offices in London, Philadelphia and Osakawith a global partner network of healthcare companies and researchorganisations. For further information, visit: www.btgplc.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
BTG